Trial · NCT02985983
A Study of Brodalumab in Subjects With Axial Spondyloarthritis (axSpA)
NCT02985983, Phase 3, Completed, Kyowa Kirin Co., Ltd.
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Study of Brodalumab in Subjects With Axial Spondyloarthritis (axSpA). Trials, record NCT02985983. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02985983
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Study of Brodalumab in Subjects With Axial Spondyloarthritis (axSpA)
- NCT number
- NCT02985983
- Status
- Completed
- Phases
- Phase 3
- Enrollment
- 159 participants, actual
- Lead sponsor
- Kyowa Kirin Co., Ltd.
- Conditions
- Axial Spondyloarthritis
- Interventions
- Brodalumab, Placebo
- First posted
- 2016-12-07
- Last updated
- 2024-07-16
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Percentage of ASAS 40 in axSpA subjects | Week 16 | |
| Secondary | Percentage of ASAS 40 in AS subjects | Week 16 | |
| Secondary | Percentage of ASAS 40 in nr-axSpA subjects | Week 16 | |
| Secondary | Ankylosing Spondylitis Disease Activity Score (ASDAS)-CRP change from baseline in axSpA subjects | Week 16 | |
| Secondary | Number of adverse events | Up to week 68 | |
| Secondary | Number of patients exposed to anti-KHK4827 antibodies | Pre-dose,Week 16,Week 32,Week 48,Week 68 or End of study | |
| Secondary | Serum KHK4827 concentration | pre-dose、Week 1、Week 2、Week 4、Week 8、Week 12、Week 14、Week 16、Week 24、Week 28、Week 32 |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers2
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02985983
GET https://conductscience.org/api/trials/v1/NCT02985983/registered